India’s Pharmaceuticals in Global Healthcare

1. At a Glance

• India is branded the "Pharmacy of the World", ranking 3rd globally by volume and 11th by value in drugs & pharmaceuticals [S2][S3].
• Sector is a dual lever: it advances public health (essential medicines, vaccines) and economic growth (exports, jobs, supply-chain resilience) [S1].
• Examinable as a cross-cutting topic in GS-II (health, India & world) and GS-III (economy, S&T, manufacturing).

2. Why in the News

• PIB Backgrounder (21 March 2026): "India's Pharmaceuticals in Global Healthcare — From Domestic Production to International Markets" [S1].
• Economic Survey 2025-26 flagged India's shift toward high-value pharma and innovation [S3].
• Pharma exports touched USD 30.5 billion in FY 2024-25; India turned net exporter of bulk drugs (surplus ₹2,280 crore in FY 2024-25 vs deficit ₹1,930 crore in FY 2021-22) [S2].

3. Background & Evolution

• Post-1970 Indian Patents Act, 1970 (process patents only) enabled the generics boom.
• TRIPS-compliant Patents (Amendment) Act, 2005 reintroduced product patents.
• PLI Scheme for KSMs/DIs/APIs launched 20 March 2020, outlay ₹6,940 crore (FY21–FY30), targeting 41 bulk drugs with high import dependence [S2].
• PLI Pharma (broader) launched 2021; Bulk Drug Parks Scheme for 3 mega parks.

4. Core Static Facts

• Ministry/Department: Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers.
• Regulator: CDSCO under Ministry of Health & Family Welfare; Drugs and Cosmetics Act, 1940.
• Industry size: ~USD 50 billion (2022-23); exports ~50% of production [S2].
• Global share: ~20% of global generics supply; ~60,000 generic brands across 60 therapeutic categories [S3].
• Vaccines: ~60% of UNICEF vaccine supply; 40-70% of global DPT & BCG demand; ~90% of WHO measles vaccine demand [S3].
• PMBJP: >18,646 Jan Aushadhi Kendras as of 28 Feb 2026 [S3].
• PLI Bulk Drugs: 48 projects selected; 34 commissioned for 25 bulk drugs (Dec 2024) [S2].
• PLI investment realised (Mar 2025): ₹37,306 crore vs commitment ₹17,275 crore; cumulative sales ₹2,66,528 crore (exports ₹1,70,807 crore) [S2].

5. Multi-Dimensional Analysis

Economic - Sector size ~USD 50 bn; exports USD 30.5 bn FY25; major forex earner [S2][S3]. - PLI exceeded investment target 2x by year 3 [S2]. - Transition from net importer to net exporter of bulk drugs by FY25 [S2].

Geopolitical / Strategic - Supplies vaccines to UNICEF, WHO, GAVI — soft-power asset ("Vaccine Maitri" lineage) [S3]. - API dependence on China (~60-70% historically) drove Atmanirbhar Bharat push via bulk drug parks [S2].

Scientific / Technological - Economic Survey 2025-26: shift to biosimilars, complex generics, CRAMS, novel molecules [S3]. - R&D intensity still low (~7-8% vs MNC ~15-20%).

Social / Public Health - Generics & Jan Aushadhi (>18,646 outlets) lower out-of-pocket expenditure [S3]. - Underpins universal access in LMICs (Africa, SE Asia).

Administrative / Governance - Concurrent List subject; CDSCO + State drug controllers (federal split — quality enforcement gap). - Schedule M (revised 2023) — GMP norms phased for MSMEs.

6. Recent Developments (last 12-18 months)

• 21 March 2026: PIB Backgrounder on pharma in global healthcare [S1].
• FY 2024-25: Pharma exports USD 30.5 bn; bulk drug trade flips to surplus [S2][S3].
• March 2025: PLI cumulative investment ₹37,306 crore [S2].
• December 2024: 34 of 48 PLI bulk-drug projects commissioned [S2].
• Economic Survey 2025-26: high-value pharma & innovation thrust [S3].

7. Prelims Hooks

• India ranks 3rd by volume, 11th by value in global pharma [S2][S3].
• ~20% of global generics supply is from India [S3].
• India supplies ~60% of UNICEF's vaccines and ~90% of WHO's measles vaccine demand [S3].
• PLI for Bulk Drugs: outlay ₹6,940 crore, 41 identified molecules, launched 20 March 2020 [S2].
• Pharma exports FY 2024-25: USD 30.5 billion [S3].
• Bulk drug trade balance: deficit ₹1,930 cr (FY22) → surplus ₹2,280 cr (FY25) [S2].
• Jan Aushadhi Kendras: >18,646 as of 28 Feb 2026 [S3].
• Implementing Department: Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers (NOT MoHFW).
• Regulator CDSCO under MoHFW; statute: Drugs and Cosmetics Act, 1940.
• India manufactures ~60,000 generic brands across 60 therapeutic categories [S3].
• PLI Pharma cumulative sales ₹2,66,528 crore, exports ₹1,70,807 crore (Mar 2025) [S2].

8. Mains Relevance

• GS-II: Health; India and the World (vaccine diplomacy); issues relating to development of social sectors.
• GS-III: Indian economy — growth & employment; S&T indigenisation; Atmanirbhar Bharat.
• Question stems: 1. "India's emergence as the 'Pharmacy of the World' is as much a story of policy choices as of scientific capacity." Discuss. 2. "Critically evaluate the Production Linked Incentive (PLI) scheme in reducing India's API import dependence." 3. "How does India's pharmaceutical sector serve as an instrument of soft power and economic diplomacy?"

9. Related Topics to Study Next

• TRIPS & Doha Declaration — compulsory licensing, Natco vs Bayer (Nexavar).
• Patents (Amendment) Act 2005 & Section 3(d) — Novartis case anchor.
• PMBJP / Jan Aushadhi — generics access policy.
• Vaccine Maitri & COVAX — diplomacy angle.
• PLI schemes (14 sectors) — manufacturing policy.
• National Medical Devices Policy 2023 — adjacent sector.
• CDSCO & DCGI — drug regulation architecture.
• AB-PMJAY & out-of-pocket expenditure — demand-side health linkage.

10. Common Errors / Trap Areas

• Confusing 3rd by volume vs 11th by value — both ranks must be stated correctly [S2][S3].
• Assuming pharma sits under MoHFW — production lies with Dept. of Pharmaceuticals, M/o Chemicals & Fertilizers; regulation (CDSCO) with MoHFW.
• Mixing PLI for Bulk Drugs (₹6,940 cr, 41 APIs, 2020) with broader PLI Pharma (2021).
• Drugs & Cosmetics Act is 1940, not 1948 (ESIC) or 1954 (Drugs & Magic Remedies).
• Jan Aushadhi outlets are Kendras, run under BPPI, not directly by MoHFW.

11. Sources

• [S1] India's Pharmaceuticals in Global Healthcare — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2243248 — (tier 1)
• [S2] PLI Scheme / Bulk Drugs — Press releases — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2121425 ; https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=2081491 — (tier 1)
• [S3] India: The World's Pharmacy & Economic Survey 2025-26 — https://static.pib.gov.in/WriteReadData/specificdocs/documents/2024/aug/doc2024822379301.pdf ; https://www.pib.gov.in/PressReleasePage.aspx?PRID=2221080 — (tier 1)